Editors:
- Contemporary monograph on the treatment of breast cancer.-
- Gives a comprehensive account of drugs for HER2-positive breast cancer.-
- A valuable source of information for researchers and clinicians from the fields of oncology and pharmacology
- Includes supplementary material: sn.pub/extras
Part of the book series: Milestones in Drug Therapy (MDT)
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (6 chapters)
-
Front Matter
-
Back Matter
About this book
Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.
Reviews
From the reviews:
“This book takes readers on a journey from HER-2 signalling to therapeutic use of trastuzumab in the neoadjuvant, adjuvant and metastatic settings. … It is a tour-de-force and should be essential reading for anyone setting out in the HER-2 research field. … Overall, this small book covers the topic of HER-2 inhibition very well in a field that is rapidly changing.” (S. W. Wong and R. M. Lowenthal, Inflammation Research, Vol. 61, 2012)
Editors and Affiliations
-
Medical University of Vienna, Department of Medicine I, Institute for Cancer Research, Vienna, Austria
Maria Sibilia
-
Medical University of Vienna, Department of Medicine I, Comprehensive Cancer Center, Vienna, Austria
Christoph C. Zielinski, Thomas W. Grunt
-
Medical University of Vienna, Department of Medicine I, Comprehensive Cancer Centre, Vienna, Austria
Rupert Bartsch
Bibliographic Information
Book Title: Drugs for HER-2-positive Breast Cancer
Editors: Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas W. Grunt
Series Title: Milestones in Drug Therapy
DOI: https://doi.org/10.1007/978-3-0346-0094-1
Publisher: Springer Basel
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer Basel AG 2011
Hardcover ISBN: 978-3-0346-0093-4Published: 07 January 2011
Softcover ISBN: 978-3-0348-0318-2Published: 25 February 2013
eBook ISBN: 978-3-0346-0094-1Published: 06 January 2011
Series ISSN: 2296-6056
Series E-ISSN: 2296-6064
Edition Number: 1
Number of Pages: X, 110
Topics: Pharmacology/Toxicology, Oncology, Cancer Research, Antibodies, Immunology, Internal Medicine